136 related articles for article (PubMed ID: 22710897)
1. Biological prognostic markers in diffuse large B-cell lymphoma.
Perry AM; Mitrovic Z; Chan WC
Cancer Control; 2012 Jul; 19(3):214-26. PubMed ID: 22710897
[TBL] [Abstract][Full Text] [Related]
2. Prognostication of diffuse large B-cell lymphoma in the rituximab era.
Ninan MJ; Wadhwa PD; Gupta P
Leuk Lymphoma; 2011 Mar; 52(3):360-73. PubMed ID: 21275631
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium).
de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Lee A; Sander B; Thorns C; Campo E; Molina T; Hagenbeek A; Horning S; Lister A; Raemaekers J; Salles G; Gascoyne RD; Weller E
J Clin Pathol; 2009 Feb; 62(2):128-38. PubMed ID: 18794197
[TBL] [Abstract][Full Text] [Related]
4. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
5. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
[TBL] [Abstract][Full Text] [Related]
6. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
7. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
8. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome.
Lossos IS
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):108-11. PubMed ID: 18162230
[TBL] [Abstract][Full Text] [Related]
10. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
11. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
Miyazaki K
Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
[TBL] [Abstract][Full Text] [Related]
12. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
14. Emerging prognostic factors in diffuse large B cell lymphoma.
Gascoyne RD
Curr Opin Oncol; 2004 Sep; 16(5):436-41. PubMed ID: 15314511
[TBL] [Abstract][Full Text] [Related]
15. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.
Oh YH; Park CK
J Korean Med Sci; 2006 Jun; 21(3):397-405. PubMed ID: 16778379
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
18. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
19. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
20. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
